Baidu
map

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请,用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-02-20 不详 MedSci原创

Karyopharm Therapeutics宣布,美国食品药品监督管理局(FDA)已接受其补充新药申请(sNDA)寻求将口服核出口选择性抑制剂XPOVIO(selinexor)片剂,用于先前已接受过至少两种治疗方案的复发或难治的弥漫性大B细胞淋巴瘤(RR DLBCL)成年患者。FDA还批准了Karyopharm的优先审查请求。

Karyopharm Therapeutics宣布,美国食品药品监督管理局(FDA)已接受其补充新药申请(sNDA)寻求将口服核出口选择性抑制剂XPOVIO(selinexor)片剂,用于先前已接受过至少两种治疗方案的复发或难治的弥漫性大B细胞淋巴瘤(RR DLBCL)成年患者。FDA还批准了Karyopharm的优先审查请求。

XPOVIO是口服的核出口选择性抑制剂的化合物,通过选择性结合并抑制核输出蛋白1(XPO1,也称为CRM1)发挥功能。XPOVIO阻断了肿瘤抑制因子、生长调节蛋白和抗炎蛋白的核输出,导致这些蛋白在细胞核中积累并增强了其在细胞中的抗癌活性。

如果获得FDA的行销许可,Karyopharm计划在2020年中期之前在美国将XPOVIO商业化。该公司还希望在2020年向欧洲药品管理局提交一份营销许可申请,申请XPOVIO的有条件批准。

XPOVIO治疗复发性或难治性DLBCL患者,已获得FDA的孤儿药和快速通道认证。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
    2020-12-10 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
    2020-12-18 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
    2020-08-16 chshh86
  9. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1744202, encodeId=e94c1e44202b4, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Sat Mar 14 02:28:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787646, encodeId=d0a91e876466c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Dec 10 07:28:00 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984675, encodeId=d24b19846e5dd, content=<a href='/topic/show?id=c3f1425e1b3' target=_blank style='color:#2F92EE;'>#复发或难治的弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42571, encryptionId=c3f1425e1b3, topicName=复发或难治的弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Mar 10 11:28:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852276, encodeId=891f18522e65b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 18 11:28:00 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702621, encodeId=702a1e026210c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Jun 26 10:28:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922951, encodeId=ad45192295176, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun May 17 20:28:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028302, encodeId=709f20283021b, content=<a href='/topic/show?id=ed7b901419c' target=_blank style='color:#2F92EE;'>#补充新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90141, encryptionId=ed7b901419c, topicName=补充新药申请)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Fri Jul 24 08:28:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685447, encodeId=eb6d168544e7c, content=<a href='/topic/show?id=1d5b1885342' target=_blank style='color:#2F92EE;'>#Xpovio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18853, encryptionId=1d5b1885342, topicName=Xpovio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=516628191616, createdName=chshh86, createdTime=Sun Aug 16 09:28:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290168, encodeId=92ce12901680b, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Feb 22 03:28:00 CST 2020, time=2020-02-22, status=1, ipAttribution=)]

相关资讯

FDA授予DSG3-CAART治疗寻常型天疱疮的孤儿药资格

Cabaletta Bio是一家临床阶段的生物技术公司,今日宣布,美国FDA已授予候选药物DSG3-CAART孤儿药物资格,用于治疗寻常型天疱疮(PV)。

FDA授予Losmapimod治疗面肩肱型肌营养不良症(FSHD)的孤儿药资格

Fulcrum是一家临床阶段的生物制药公司,致力于改善罕见疾病患者的生活,今日宣布,美国FDA授予了Losmapimod孤儿药资格(ODD),Losmapimod是一种选择性p38α/β丝裂原活化蛋白激酶(MAPK)抑制剂,用于治疗FSHD。

默克针对革兰氏阴性菌感染的抗生素组合Recarbrio,获得FDA的优先审查

美国食品和药物管理局(FDA)已开始对默克的抗生素组合药物Recarbrio进行审查,该药可为难以治疗的革兰氏阴性菌感染提供新的选择。

诺华的MET抑制剂卡马替尼治疗非小细胞肺癌,获得FDA授予优先审查

诺华制药宣布,美国食品药品监督管理局(FDA)接受了MET抑制剂卡马替尼(INC280)的新药申请(NDA)并给予了优先审查,用于一线治疗和先前治疗过的局部晚期或转移性MET外显子14跳跃(METex14)突变的非小细胞肺癌(NSCLC)患者。

默克向FDA申请,将Belsomra用于治疗阿尔茨海默氏症患者的睡眠障碍

默克公司向FDA申请批准其失眠药物Belsomra的新适应症,用于治疗轻度至中度阿尔茨海默氏病患者的睡眠障碍。

FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla

Agile Therapeutics表示,FDA已批准每周一次的避孕贴剂Twirla透皮系统上市,该系统可提供乙炔雌二醇和左炔诺孕酮的每日剂量。

Baidu
map
Baidu
map
Baidu
map